|
|
|
|
|
Discovery & Pipeline.
Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms, , Thrombotargets is continuously creating a novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
|
|
|
News
| • Thrombotargets has successfully accomplished a new internal financing round of 1,8 M USD on Q1 2009 |
| • Thrombotargets considered one of the leading Biotech companies within the growing and successful cluster of Catalonia, Spain. |
| • Thrombotargets renews its commitment with PMT (Mediterranean Park Technology) |
Upcoming events
| • Thrombotargets to attend EUROBIOTECH FORUM 2009 |
| • Thrombotargets Corp. will attend BIO2008, the International Partnering Conference, San Diego, US, 2008. |
|
|
|